EryDex Fails to Meet Primary End Point for Pediatric Ataxia-Telangiectasia in Phase 3 ATTeST Trial

Published Date: 29 Aug 2024

EryDex did not meet its primary end point possibly because of delays in treatment reducing the number of patients who received the agent, and different treatment effects based on age.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Year in Review: Chronic Lymphocytic Leukemia

2.

According to a study, white Americans are overdiagnosing melanoma at an alarming rate.

3.

Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies

4.

The First Gene Therapy Provides a Durable Response for Non-Muscle-Invasive Bladder Cancer.

5.

Canine Cancer Vaccine: A Potential Resurrection? U.S. KK. Snubs Enertu.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot